Further experimental results show that erlotinib pretreatment also prevented EGF-induced Rab35 activity in HeLa cells (Figure 4C) as well as in the gastric cancer cell line SGC-7901 (data not shown). The gene discussed is RAB35; the disease is gastric cancer.